• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, August 5, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

PCORI Board approves $45 million to support research on opioid use disorders, cancer pain

Bioengineer by Bioengineer
April 16, 2019
in Cancer
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

WASHINGTON (April 16, 2019) — The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors today approved $44.6 million to fund 12 studies comparing the best ways to treat a range of health conditions that impose high burdens on patients, caregivers and the healthcare system.

The newly approved awards include four focused on improving the availability and effectiveness of treatment for opioid use disorder (OUD), which affects 2.5 million Americans aged 12 and older, including 8 to 12 percent of people prescribed opioids for chronic pain. Three awards focus on patients treated for OUD in doctors’ offices with the medication buprenorphine and seek to determine which psychosocial treatments work best in combination with that medication to help these patients abstain from opioid use:

  • A $5.5 million Philadelphia College of Osteopathic Medicine study comparing three psychosocial treatments for people being treated at federally qualified health centers. The study looks at which kind of psychosocial treatment — cognitive behavioral therapy, peer recovery support or a combination of both — is most effective.
  • A $4.9 million RAND Corporation study of whether incorporating a patient’s support system into their treatment with buprenorphine can improve outcomes. The study will examine whether a counseling program for someone close to the patient, such as a family member, spouse or friend, can improve recovery.
  • A $4.4 million Johns Hopkins School of Medicine project comparing ways to improve outcomes by using patient incentives. One method will be standard care and two others will involve incentives for people who use buprenorphine daily to stay on their medication and not use drugs.

The fourth opioids-related award is $5.6 million for a Yale University School of Medicine study comparing two approaches for supporting obstetricians who treat pregnant women with OUD with medication-assisted treatment. One is a collaborative care model where a care manager supports the obstetrician with patient screening, intake, education, treatment and care coordination. The other uses remote education to provide obstetricians with expert mentorship and guidance via video conferencing. The study looks at which model is better for patients.

“PCORI is committed to funding studies across the broad range of issues that need to be considered if we are to reduce the toll that opioid use disorders, and inappropriate use of opioids more broadly, is taking on patients, their families and the healthcare system,” said PCORI Executive Director Joe Selby, MD, MPH. “We believe PCORI’s approach to helping combat this major public health challenge — by comparing which care approaches work best, based on relevant outcomes — can help patients and their doctors make better-informed decisions about their treatment options.”

These latest awards bring to nearly three-dozen the number of patient-centered comparative clinical effectiveness (CER) studies PCORI has funded related to opioid use. These are part of PCORI’s broader focus on addressing the opioid epidemic by finding better ways to help people manage chronic pain, prevent inappropriate opioid use, improve long-term pain management while reducing the risk opioids can pose, and increase access to and quality of OUD treatment.

Other awards approved include:

  • $5.7 million to examine strategies for improving treatment of insomnia in rural areas, looking at how well a commonly prescribed drug works compared with cognitive behavioral therapy
  • $5.6 million for a study comparing ways to enhance prenatal care to improve maternal and child health.
  • $2.7 million in funding for a study comparing two non-drug approaches – acupuncture and massage therapy — to improve care for severe pain in people with cancer

Details of all projects approved for funding by the Board appear on PCORI’s website. All awards were approved pending a business and programmatic review by PCORI staff and issuance of formal award contracts.

With these latest awards, PCORI has invested $2.4 billion to fund more than 460 patient-centered CER studies and to support other projects designed to enhance CER methods and the infrastructure necessary to conduct CER rigorously and efficiently.

###

Media Contact
Mary McNamara
[email protected]
https://www.pcori.org/news-release/pcori-board-approves-45-million-support-research-improving-treatment-opioid-use

Tags: AddictioncancerClinical TrialsGynecologyHealth CareMedicine/HealthMetabolism/Metabolic DiseasesPain
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

48th Annual UNC Lineberger Scientific Symposium Highlights Advances in Cancer Discovery and Patient Care

August 5, 2025
Carnosol’s Cancer Fight: From Molecules to Medicine

Carnosol’s Cancer Fight: From Molecules to Medicine

August 5, 2025

Chronic CMV Infection Boosts Melanoma Immunotherapy Survival

August 5, 2025

Carvedilol Boosts Paclitaxel Effect in Resistant Gastric Cancer

August 5, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Neuropsychiatric Risks Linked to COVID-19 Revealed

    73 shares
    Share 29 Tweet 18
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    46 shares
    Share 18 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

New Trematode Species Found in Mediterranean Cardinal Fish

Predator Traits Shape Nanoplastic Uptake in Aquatics

Attachment Styles Link Emotions to Gaming Disorder Risks

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.